Singing Therapy for Supragastric Belching: A Randomized Trial Challenges Conventional Breathing Therapy

What the trial investigated

The study was a multicenter randomized controlled trial conducted at two tertiary gastroenterology centers in China between October 2024 and April 2025. Investigators screened 92 patients with supragastric belching and randomly assigned 72 patients in a 1:1 ratio to either structured singing therapy or diaphragmatic breathing for one week. Four patients in each group withdrew during the intervention, leaving 32 patients per group who completed treatment and 30 per group who completed one-month follow-up.

Patients were diagnosed according to Rome IV criteria. Baseline demographic characteristics, belching symptom severity, gastrointestinal symptom scores, quality-of-life measures, anxiety scores, and depression scores were reported as similar between groups.

The primary outcome was treatment response, defined as at least a 50% reduction in belching visual analog scale scores. Secondary outcomes included health-related quality of life, gastrointestinal symptom severity, anxiety, depression, and treatment acceptability. Outcomes were assessed at baseline, immediately after the one-week intervention, and again at one month.

What singing therapy actually involved

The singing intervention was structured rather than casual. Participants performed five-minute sessions three times daily for one week, with additional sessions during belching episodes. They sang one of four standardized Chinese folk songs while focusing on diaphragmatic breathing, sustained vocalization, abdominal movement, and visual and tactile feedback.

The comparator group received individualized instruction from a gastroenterologist and practiced five-minute diaphragmatic breathing exercises three times daily, with additional sessions when symptoms occurred.

This distinction matters. The study did not compare singing with no treatment, nor did it compare singing with vague breathing advice. It compared two active behavioral approaches over the same short treatment duration. That strengthens the clinical relevance of the finding, although it does not eliminate important limitations.

The main finding: stronger short-term response with singing

After one week, the response rate was higher with singing therapy than with diaphragmatic breathing. In the AGA report, 72% of patients assigned to structured singing met the response threshold at one week compared with 39% assigned to diaphragmatic breathing. At one month, the separation persisted: 50% of patients in the singing group still met response criteria compared with 31% in the diaphragmatic breathing group.

The journal abstract reports similar results using precise trial figures: 72.2% vs 38.9% immediately after intervention, with P = .004, and 50.0% vs 30.6% at one-month follow-up, with P = .032.

The per-protocol analysis followed the same direction, with response rates of 81% for singing therapy versus 44% for diaphragmatic breathing. Belching symptoms improved in both groups, but the singing group had greater symptom reduction immediately after treatment, and the benefit in belching relief was maintained at follow-up.

This is clinically meaningful because diaphragmatic breathing is already used in practice. The trial does not merely show that singing can help compared with doing nothing. It suggests that a more engaging respiratory-vocal exercise may produce greater short-term improvement than a familiar behavioral comparator.

Quality of life and acceptability: the implementation signal

Symptom response is important, but behavioral therapies succeed or fail partly on acceptability. The trial found that quality of life improved more with singing therapy immediately after treatment. Specifically, EuroQol visual analog scale scores increased more with singing than with diaphragmatic breathing at treatment completion. Scores declined somewhat in both groups by one month but remained higher than baseline.

Other secondary outcomes, including gastrointestinal symptom severity, anxiety, and depression, improved in both groups without a broad advantage for singing. Depression scores differed at one month, but investigators considered this unlikely to be clinically meaningful because patients with severe anxiety or depression had been excluded.

Treatment acceptability may be one of the most interesting signals. Responders rated the intervention as more acceptable than nonresponders, and patients assigned to singing therapy rated treatment acceptability higher than those assigned to diaphragmatic breathing. Higher acceptability was associated with greater improvement in belching symptoms.

This does not prove that acceptability caused better outcomes. Patients who improve may naturally rate an intervention more favorably. Still, the association is clinically plausible and relevant. If a patient finds a behavioral exercise engaging, they may practice it more consistently, especially when symptoms occur.

Which patients might benefit most?

The trial’s multivariable analysis identified three independent predictors of treatment response: assignment to singing therapy, older age, and greater baseline belching severity. Patients assigned to singing therapy were reported to be nearly seven times more likely to achieve treatment response than those assigned to diaphragmatic breathing. Sex, body mass index, gastrointestinal symptom severity, quality-of-life scores, anxiety, and depression were not associated with treatment response.

This should be interpreted cautiously. The investigator commentary emphasized that age and baseline severity findings came from an exploratory predictor analysis rather than a prespecified subgroup comparison. Clinicians should therefore not use age or severity as strict eligibility criteria for singing therapy.

A practical interpretation is narrower: older patients and those with more severe symptoms may be promising candidates for future research, and possibly for clinical experimentation where behavioral therapy is already being used. But the evidence is not strong enough to define a treatment-selection rule.

What clinicians should conclude now

The trial supports the view that structured singing therapy is a credible behavioral intervention for supragastric belching, at least in the short term and in the studied population. It was superior to diaphragmatic breathing for the primary response outcome after one week, and the difference remained statistically significant at one month.

What clinicians should not conclude is equally important.

This study does not establish singing therapy as a universal first-line standard. Follow-up was limited to one month. Blinding was not possible because the interventions were behavioral. Adherence was self-reported. The symptom visual analog scale used to assess belching symptoms was not formally validated. Diagnosis was based on clinical history and observation rather than high-resolution esophageal manometry or pH-impedance testing, which means diagnostic misclassification cannot be fully excluded.

Generalizability is another issue. The study was conducted in Chinese tertiary centers, and the intervention used culturally familiar Chinese folk songs. It is plausible that structured singing could be adapted across cultures, but the evidence does not yet prove that any song, language, delivery method, or patient population will produce the same results.

How this may influence practice

For now, singing therapy is best viewed as an early but clinically interesting behavioral option, not a practice-changing mandate. It may be especially relevant for patients who understand the behavioral mechanism of supragastric belching but struggle to practice standard diaphragmatic breathing consistently.

In a clinical setting, the study may encourage gastroenterologists to think more creatively about behavioral retraining. The mechanism being targeted is not the song itself, but coordinated diaphragmatic, abdominal, respiratory, and glottal control. Singing may offer a structured, memorable way to practice those elements.

This could also strengthen collaboration between gastroenterologists, speech-language therapists, psychologists, and motility specialists. A standardized protocol, culturally adaptable song selection, training materials, adherence monitoring, and objective physiologic confirmation would be needed before broader implementation.

The most responsible message for patients is not “singing cures belching.” It is that a small randomized trial suggests structured singing exercises may reduce supragastric belching more than conventional diaphragmatic breathing over short-term follow-up, but longer and more diverse studies are needed.

Remaining evidence gaps

Several questions remain unanswered. Would the benefit persist at three, six, or twelve months? Would longer treatment produce stronger or more durable results? Would patients with pH-impedance-confirmed supragastric belching respond similarly? Can the intervention be delivered by gastroenterologists, speech therapists, digital tools, or group sessions? How much practice is necessary, and what predicts adherence?

The trial authors are reportedly preparing follow-up work to assess whether patients benefit from extending the treatment course and from longer follow-up.

Those next studies matter because supragastric belching is often chronic and relapse-prone. A one-week response is encouraging, but durable behavioral retraining is the real clinical endpoint.

Clinical Takeaway

Structured singing therapy is an intriguing, low-risk behavioral intervention for supragastric belching. In a multicenter randomized trial of 72 patients, it produced higher short-term response rates than diaphragmatic breathing, with benefits persisting at one month. The study is clinically relevant because it tests an active, engaging alternative to standard breathing exercises. However, the evidence remains early: follow-up was short, diagnosis was not physiologically confirmed in all patients, the symptom scale was not formally validated, and cultural adaptation is uncertain.

For gastroenterologists, the study should expand the conversation around behavioral therapy for supragastric belching. It should not yet rewrite treatment algorithms.

Five key clinical takeaways

1. Study design: Multicenter randomized controlled trial comparing structured singing therapy with diaphragmatic breathing in 72 patients with Rome IV–defined supragastric belching.

2. Primary outcome: Singing therapy achieved higher treatment response, defined as at least 50% reduction in belching visual analog scale score, at one week and one month.

3. Clinical relevance: Singing may improve engagement with respiratory-abdominal retraining, a major practical barrier in behavioral treatment.

4. Limitations: Short follow-up, lack of blinding, self-reported adherence, nonvalidated belching VAS, and absence of routine physiologic confirmation limit certainty.

5. Practice signal: Early but interesting; reasonable to view as an alternative or complementary behavioral strategy, not established guideline-changing therapy.

Source reference and link

Shang H, Ma H, Xu Z, Gao Y, Bai T, Hou X. “Singing Therapy versus Diaphragmatic Breathing for Supragastric Belching: A Multicenter Randomized Controlled Trial.” Clinical Gastroenterology and Hepatology, published online July 2026.

Additional source: AGA / GI & Hepatology News report, “Singing therapy outperformed breathing exercises in supragastric belching trial,” 22 July 2026.